Immix Biopharma, Inc. (IMMX) earnings date
Feb 11, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 35% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 1 releases on file; at least 4 are needed |
Last 1 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | after close | 43 | 8-K |
What they guided beta
| Q3 FY2026 | "On Monday, December 14, 2026, NXC-201 NEXICART-2 interim clinical data will be presented at the 68 th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA." exhibit |
| Q3 FY2026 | "30, 2026, which is expected to provide operating runway into mid-2028." exhibit |
| Q3 FY2026 | "The Amyloidosis market was $6.2 billion in 2025, and is expected to reach $6.6 billion in 2026, according to Grand View Research." exhibit |
| Q3 FY2026 | "He, Karin McIntosh and other new team members, including accelerating the planned path to commercialization, cash, cash equivalents, and marketable securities expected to provide operating runway into mid-2028 and expected growth of the AL amyloidosis market." exhibit |
| Q3 FY2026 | "Among those factors are: (i) the risk that the estimates for the number of patients in the U.S. with relapsed/refractory AL Amyloidosis and the market size reaching not being accurate; (ii) the risk that Breakthrough Therapy designation will not expedite the development of NXC-201: (iii) the risk that further data from the ongoing Phase 1/2 clinical trials for NXC-201 will not be favorably consistent with the data readouts to date, including the risk that MRD-negativity will not translate into higher complete response rates; (iv) the risk that the Company may not be able to continue the NEXICA" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/IMMX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/IMMX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/IMMX/"><img src="https://veritasdata.dev/embed/IMMX.svg" alt="IMMX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/IMMX/)
Script
<script async src="https://veritasdata.dev/embed/IMMX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/IMMX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.